News

The company will be called Daiichi Sankyo Ireland and be headquartered in Dublin. In addition to the osteoporosis medication Evista, Daiichi Sankyo Ireland will market the anti-hypertensive product

The new patent’s allowed claims include methods of treating a broad spectrum of viral infections, including HIV, influenza, hepatitis C virus and cytomegalovirus, using one or more anti-phospholipid

The CE Mark allows Kinetic Concepts (KCI) to begin marketing Strattice in all 27 member states. Strattice has previously received 510(k) clearance from the FDA and has been

The Acord trial will include four randomized, double-blind, placebo-controlled doses in approximately 120 patients with severe coronary heart disease. Approximately 30 sites are expected to participate. CardioVascular BioTherapeutics’s

The patents cover a technology that allows for the rapid characterization of the potency of bone marrow-derived cells in the treatment of cardiovascular diseases. The potency of stem

The two-armed, randomized clinical trial has enrolled 200 patients at sites in the Philippines, Korea, India, Malaysia, Thailand, Hong Kong, Singapore, Serbia, Poland, Croatia, and Italy. The primary

Under the terms of the agreement, Watson will acquire the portfolio of products for an upfront payment of $36 million and will make additional payments to Teva when

Abraxis has developed an extensive clinical program that the company believes will form the basis for new indications for Abraxane as well as other product candidates for which

Under this collaboration, Harvard Medical School (ICCB-L) will utilize the CellaxessHT system, a high throughput transfection enabling reagent-free delivery system, for genome-wide RNAi delivery to biologically relevant cell